Ocugen, Inc. (OCGN)
1.32
-0.01
(-0.75%)
USD |
NASDAQ |
Sep 02, 15:08
Ocugen Research and Development Expense (Annual) : 37.36M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 37.36M |
| December 31, 2024 | 30.16M |
| December 31, 2023 | 38.87M |
| December 31, 2022 | 55.68M |
| December 31, 2021 | 35.11M |
| December 31, 2020 | 12.44M |
| December 31, 2019 | 8.086M |
| Date | Value |
|---|---|
| December 31, 2018 | 10.32M |
| December 31, 2017 | 15.57M |
| December 31, 2016 | 21.58M |
| December 31, 2015 | 23.24M |
| December 31, 2014 | 25.86M |
| December 31, 2013 | 11.95M |
| December 31, 2012 | 11.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Biogen, Inc. | 1.481B |
| Gilead Sciences, Inc. | 5.688B |
| MannKind Corp. | 66.35M |
| Vertex Pharmaceuticals, Inc. | 3.754B |